DES PLAINES, Ill., July 13 (Reuters) - Abbott Molecular, the fast-growing unit of Abbott Laboratories (ABT) that makes genomic and other medical tests, said on Monday it entered into an agreement with British drugmaker GlaxoSmithKline (GSK) to develop a test to screen for lung cancer.
The company said the test will focus on an antigen called MAGE-A3 and will screen for non-small lung cancer tumors.
The financial terms of the deal were not disclosed.
In an interview, Abbott Molecular President Stafford O'Kelly said the company will be announcing a similar collaboration with another pharmaceutical company within 30 days.
The diagnostic molecular test Abbott Molecular is developing with Glaxo will be based on its so-called PCR, or polymerase chain reaction, technology. It is intended to screen non-small cell lung cancer tumors for expression of the MAGE-A3 antigen.
"We've been talking about personalized medicine for 15, 20 years. This is just the beginning," O'Kelly said.
Currently, there are no nucleic acid-based tests approved by the U.S. Food and Drug Administration for use in identifying patients who may derive treatment benefits from targeted NSCLC therapies.
Des Plaines, Illinois-based Abbott Molecular, whose sales grew 25 percent year over year to almost $270 million in 2008[this is about 1% of ABT’s total sales], makes genomic tests for chromosome changes associated with congenital disorders and cancer.
It also makes instruments and reagents, a chemical agent for use in chemical reactions, used to conduct sophisticated analysis of patient DNA and RNA, a biologically important type of molecule that consists of a long chain of nucleotide units.‹
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.